Clinical Trial Update: Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating azacitidine plus deferasirox (ICL670) for higher-risk myelodysplastic syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Deferasirox (Deferasirox)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED